Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 16/20 | 0.66 |
| ▸ | GRPR | P30550 | 14/20 | 0.66 |
| ▸ | FPR1 | P21462 | 4/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.60 |
| ▸ | FPR2 | P25090 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250547 | 0.89 | NMBR (0.71) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6250550 | 0.89 | NMBR (0.71) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6250730 | 0.87 | NMBR (0.74) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6249989 | 0.83 | NMBR (0.70) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6250000 | 0.82 | NMBR (0.70) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6250486 | 0.82 | NMBR (0.70) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6252074 | 0.82 | NMBR (0.71) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6814542 | 0.81 | NMBR (0.66) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6250696 | 0.81 | NMBR (0.66) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6249779 | 0.81 | NMBR (0.70) | NMBRGRPRFPR1AGTR1GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334100-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040469-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |